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See Article, pages 995–999Despite two decades of research in antiviral therapy, we still have
not overcome a roughly 50% failure rate in the treatment of
patients infected with the hepatitis C virus (HCV). Understanding
the interactions between host and virus seems to be a prerequi-
site for any new therapeutic approach. Multiple axes of interac-
tion have been suggested: cytokines, alterations of intracellular
signaling and metabolism e.g. of fatty acids. An imbalanced iron
homeostasis is another one: pathological iron deposits have been
observed in about 50% of patients with chronic HCV infection.
Increased hepatic iron stores are not a mere innocent bystander,
but an important independent risk factor for the development of
hepatocellular cancer (HCC) in HCV-infected patients [1]. In addi-
tion, we have learnt from hereditary hemochromatosis that iron
overload is one of the most proﬁbrogenic and carcinogenic fac-
tors increasing the risk of HCC by approximately 200-fold [2].
The combination of free iron and reactive oxygen species (ROS)
leads to the production of highly toxic hydroxyl radicals via the
Fenton reaction causing severe cell damage. Since increased
hepatic oxidative stress is considered a key factor in chronic
HCV infection and coexists with increased levels of iron, progres-
sion of liver disease by toxic radicals is very likely.
The underlying mechanisms of the hepatic iron accumulation
in HCV-infected livers are still poorly understood and available
data remain mostly descriptive: parenchymal iron accumulation
in HCV patients has been linked to suppressed levels of the sys-
temic iron hormone hepcidin [3,4]. These studies suggest that
iron accumulation by HCV is somehow comparable to hereditary
hemochromatosis where an inadequate hepcidin response to
replenished iron stores is a key feature [5] leading to unrestricted
duodenal iron absorption and iron release from macrophages via
the iron transporter ferroportin [6]. In addition, several other
genes previously not related to iron metabolism are also dis-
cussed that potentially contribute to iron accumulation in HCV
[7].
The work of Fillebeen and Pantopoulos in the present issue of
the Journal of Hepatology leads the discussion about iron and
HCV one step further, by demonstrating that iron directly blocks
viral replication [8]. In the previous work the authors had shown
that iron can exert direct antiviral effects. Thus, iron binds tightlyJournal of Hepatology 20
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inhibits its catalytic activity by displacing magnesium from the
enzymatically active site [9]. The authors validated these ﬁndings
in a subgenomic HCV replicon model, where administration of
exogenous iron blocked viral replication and attenuated the pro-
duction of viral RNA and proteins [9]. More interestingly, the data
suggested that expression of the subgenomic HCV replicon leads
to an iron-poor phenotype in host Huh7 cells, possibly to bypass
the iron-dependent block in viral replication [10]. In the present
issue of the Journal, they show that the administration of exoge-
nous iron drastically inhibits the progression of HCV infection in
permissive Huh7.5.1 cells, obviously independent of the HCV
genotype.
These ﬁndings deserve particular attention in light of clinical
data where HCV patients with hereditary iron overload, due to
mutations in HFE, paradoxically respond better to antiviral
therapy [11–13]. Despite potential disturbances in macrophage
function due to iron overload, it is tempting to speculate that
increased hepatic iron content may contribute to viral RNA clear-
ance and antagonize the relapse of HCV infection following ther-
apy (Fig. 1). Fillebeen and Pantopoulos suggest, in another
publication [10], that HCV-infected hepatocytes tend to accumu-
late iron which suppresses viral infection while the virus has
strategies to eliminate iron (Fig. 1). While increasing intracellular
iron levels reduced HCV replication, preloading of Huh7.5.1 cells
with iron failed to protect them against HCV infection, suggesting
that the iron bound to ferritin is unavailable for binding to NS5B
and the active agent is free intracellular iron only. To achieve spe-
ciﬁc intracellular iron loading and to avoid potentially confound-
ing effects of heme oxygenase 1, the authors used a speciﬁc cell
permeable iron donor (Fe-SIH) instead of the routinely used
iron-donor hemin. This speciﬁc iron donor may also explain the
more profound effects on viral replication as compared to previ-
ous reports using FeCl3 or iron-loaded lactoferrin.
Why then does iron overload secondary to HCV or other
chronic liver diseases such as alcoholic liver disease not improve,
but rather worsen the clinical outcome?
Iron-induced oxidative stress very likely plays a major role.
Iron is known to affect immune responses and cytokine produc-
tion [14]. Moreover, the distribution of hepatic iron varies consid-
erably between primary and secondary iron overload states and
could also affect the clinical outcome. Thus, in hereditary10 vol. 53 j 990–992
Fig. 1. Iron accumulation of an HCV-infected hepatocyte as an antiviral
strategy? Among other sources, ROS are generated by NADPH-dependent
oxidases of innate immune cells (NOX1) and hepatocytes (NOX4) in HCV infected
livers. This oxidative stress eventually leads to intracellular iron accumulation via
suppressed hepcidin or activation of IRP1 or TfR1. This iron can clear the
hepatocyte from the virus since iron is a potent inhibitor of viral replication. In
contrast, infection with the hepatitis C virus leads to an iron-depleted hepatocyte
phenotype via still unknown mechanisms. IRP1, iron regulatory protein 1, TfR1,
transferrin receptor 1.
JOURNAL OF HEPATOLOGYhemochromatosis, iron is almost exclusively deposited in paren-
chymal cells while in secondary iron overload, including transfu-
sional siderosis, excess iron is stored mainly in macrophages. This
may explain why excess iron appeared to improve antiviral ther-
apy in HCV-infected patients with hereditary hemochromatosis
[11–13] but not in patients with secondary iron overload such
as ß-thalassemia [15]. Likewise, intravenous iron administration
does not improve the virological response of hemodialyzed
HCV-infected patients to antiviral therapy [16]. Consequently,
the inhibitory effects of iron on HCV replication may not be
exploitable for simple treatment strategies. This complex situa-
tion may also explain why studies, that analyzed the beneﬁcial
effects of iron depletion (phlebotomy) on the progression of
HCV, reported contradictory results and still warrant conﬁrma-
tion in larger cohorts [17,18].
What could be the molecular mechanisms driving iron accu-
mulation in chronic HCV infection? Interestingly, ROS do not only
contribute to the toxicity of iron but can directly lead to its intra-
cellular accumulation using speciﬁc signaling sequences. This has
been demonstrated at various regulatory levels e.g. via activation
of iron regulatory protein 1 [19], suppression of hepcidin [20], or
direct translational activation of transferrin receptor 1 [21]. The
concept summarized in Fig. 1 suggests that hepatocytes actively
accumulate iron via speciﬁc ROS-induced mechanisms as part
of their innate antiviral immunity while the virus has foundJournal of Hepatology 201evolutionary strategies to suppress iron accumulation via still
unknown mechanisms. Much more needs to be learnt about the
detailed molecular mechanisms of iron accumulation and ROS
generation during HCV infection. Unraveling where protective
iron accumulation turns into harmful iron overload will be one
of the challenging tasks for the future. Only then we will be able
to use the modulation of iron metabolism wisely in order to sup-
port antiviral strategies.Conﬂict of interest
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